Trials / Terminated
TerminatedNCT01532544
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Thrombologic ApS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating the safety and efficacy of co-administration of Iloprost and escalating doses of Eptifibatide for continuous intravenous infusion in totally 36 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ilomedin and Integrilin | Continuous infusion |
| DRUG | low molecular weight heparin. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-02-14
- Last updated
- 2016-04-22
Locations
4 sites across 2 countries: Denmark, Finland
Source: ClinicalTrials.gov record NCT01532544. Inclusion in this directory is not an endorsement.